[go: up one dir, main page]

WO2014110322A3 - Deuterated lenalidomide isotopologues for the treatment of myelodysplastic syndromes - Google Patents

Deuterated lenalidomide isotopologues for the treatment of myelodysplastic syndromes Download PDF

Info

Publication number
WO2014110322A3
WO2014110322A3 PCT/US2014/010972 US2014010972W WO2014110322A3 WO 2014110322 A3 WO2014110322 A3 WO 2014110322A3 US 2014010972 W US2014010972 W US 2014010972W WO 2014110322 A3 WO2014110322 A3 WO 2014110322A3
Authority
WO
WIPO (PCT)
Prior art keywords
isotopologues
lenalidomide
deuterated
treatment
myelodysplastic syndromes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/010972
Other languages
French (fr)
Other versions
WO2014110322A2 (en
Inventor
Roger D. Tung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concert Pharmaceuticals Inc
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of WO2014110322A2 publication Critical patent/WO2014110322A2/en
Publication of WO2014110322A3 publication Critical patent/WO2014110322A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an immunomodulatory agent.
PCT/US2014/010972 2013-01-11 2014-01-10 Substituted dioxopiperidinyl phthalimide derivatives Ceased WO2014110322A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361751512P 2013-01-11 2013-01-11
US61/751,512 2013-01-11

Publications (2)

Publication Number Publication Date
WO2014110322A2 WO2014110322A2 (en) 2014-07-17
WO2014110322A3 true WO2014110322A3 (en) 2014-09-12

Family

ID=50031578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/010972 Ceased WO2014110322A2 (en) 2013-01-11 2014-01-10 Substituted dioxopiperidinyl phthalimide derivatives

Country Status (1)

Country Link
WO (1) WO2014110322A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10077267B2 (en) 2014-04-04 2018-09-18 Intra-Cellular Therapies, Inc. Organic compounds
JP6686168B2 (en) 2016-03-25 2020-04-22 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． Organic compound
MX387784B (en) 2017-03-24 2025-03-18 Intra Celular Therapies Inc NOVEL COMPOSITIONS AND METHODS.
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
EP3843738A4 (en) 2018-08-31 2022-06-01 Intra-Cellular Therapies, Inc. Novel methods
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069379A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched lenalidomide
WO2010056344A1 (en) * 2008-11-14 2010-05-20 Concert Pharmaceuticals Inc. Substituted dioxopiperidinyl phthalimide derivaties
WO2010093434A1 (en) * 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
WO2012015986A2 (en) * 2010-07-27 2012-02-02 Concert Pharmaceuticals Inc. Substituted dioxopiperidinyl phtalimide derivatives

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
PL195916B1 (en) 1996-07-24 2007-11-30 Celgene Corp 1-oxoisoindoline and 1,3-dioxoisoindoline substituted optic isomers, pharmaceutical compositions containing them and application thereof
GB9925962D0 (en) 1999-11-02 1999-12-29 Novartis Ag Organic compounds
CN1255185C (en) 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 Pharmaceutical dosage form of amorphous nelfinavir mesylate
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
NZ540186A (en) 2002-10-31 2008-03-28 Celgene Corp Composition for the treatment of macular degeneration
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CL2004001004A1 (en) 2003-05-19 2005-03-18 Upjohn Co PHARMACEUTICAL COMBINATION THAT INCLUDES IRINOTECAN AND REVIMID TO TREAT MULTIPLE MYELOMA.
EP1660636A4 (en) 2003-08-26 2009-07-01 Univ Texas ANTICANCER VACCINES
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2004273910A1 (en) 2003-09-18 2005-03-31 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050148535A1 (en) 2003-10-30 2005-07-07 Lacasse Eric IAP nucleobase oligomers and oligomeric complexes and uses thereof
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
US20050227929A1 (en) 2003-11-13 2005-10-13 Masferrer Jaime L Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
KR20060109979A (en) 2003-12-02 2006-10-23 셀진 코포레이션 Methods and compositions for the treatment and management of hemochromatosis and anemia
US20060079461A1 (en) 2003-12-24 2006-04-13 Scios, Inc. Treatment of multiple myeloma by inhibition of p38 MAP kinase
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
ATE514434T1 (en) 2004-02-25 2011-07-15 Dana Farber Cancer Inst Inc INSULIN-LIKE GROWTH FACTOR RECEPTOR-1 INHIBITOR FOR INHIBITING TUMOR CELL GROWTH
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP2479172B1 (en) 2004-09-03 2013-10-09 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
US20060078494A1 (en) 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006039237A1 (en) 2004-09-29 2006-04-13 Cordis Corporation Pharmaceutical dosage forms of stable amorphous rapamycin like compounds
KR20070086000A (en) 2004-11-12 2007-08-27 셀진 코포레이션 Methods and compositions for using immunomodulatory compounds for the treatment and management of parasitic diseases
EP1827431A1 (en) 2004-11-23 2007-09-05 Celgene Corporation Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
CA2588990A1 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
WO2006089150A2 (en) 2005-02-18 2006-08-24 Novartis Vaccines And Diagnostics Inc. Antiangiogenic agents with aldesleukin
WO2012079022A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069379A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched lenalidomide
WO2010056344A1 (en) * 2008-11-14 2010-05-20 Concert Pharmaceuticals Inc. Substituted dioxopiperidinyl phthalimide derivaties
WO2010093434A1 (en) * 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
WO2012015986A2 (en) * 2010-07-27 2012-02-02 Concert Pharmaceuticals Inc. Substituted dioxopiperidinyl phtalimide derivatives

Also Published As

Publication number Publication date
WO2014110322A2 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
CY1123595T1 (en) BILE ACID DERIVATIVES AS FXR/TGR5 AGENTS
IL284371B (en) Amino acid compositions and methods for the treatment of liver diseases
WO2012015986A3 (en) Substituted dioxopiperidinyl phthalimide derivatives
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
EA201891489A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AMORPHOUS LENALIDOMIDE AND ANTIOXIDANT
PH12017500583B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
PH12016501457B1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IN2014MN02652A (en)
WO2017053711A3 (en) Deuterated cftr potentiators
IN2014MN02657A (en)
EA201391485A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
IN2014MN02658A (en)
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
HK1231466A1 (en) Isoindoline derivatives for use in the treatment of a viral infection
MX2015008187A (en) Deuterated alk inhibitors.
WO2014110322A3 (en) Deuterated lenalidomide isotopologues for the treatment of myelodysplastic syndromes
MX2015010829A (en) Therapeutic compounds and uses thereof.
WO2014150925A3 (en) Deuterated palbociclib
HK1217092A1 (en) Therapeutic compounds and uses thereof
MX369952B (en) Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1.
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS
TN2018000188A1 (en) Isoindole compounds
WO2016168553A8 (en) Deuterated obeticholic acid
EA201790830A1 (en) ALDOSTERONSYNTASE INHIBITORS
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14702359

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14702359

Country of ref document: EP

Kind code of ref document: A2